S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NYSE:BSX

Boston Scientific - BSX Stock Forecast, Price & News

$41.86
+0.83 (+2.02%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$41.49
$41.90
50-Day Range
$35.24
$41.62
52-Week Range
$34.98
$47.49
Volume
6.99 million shs
Average Volume
8.71 million shs
Market Capitalization
$59.84 billion
P/E Ratio
72.17
Dividend Yield
N/A
Price Target
$46.55

Boston Scientific MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11.2% Upside
$46.55 Price Target
Short Interest
Healthy
0.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.00mentions of Boston Scientific in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$2.38 M Sold Last Quarter
Proj. Earnings Growth
11.36%
From $1.76 to $1.96 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.97 out of 5 stars

Medical Sector

43rd out of 1,108 stocks

Surgical & Medical Instruments Industry

5th out of 112 stocks

BSX stock logo

About Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Stock Up 0.1 %

Shares of BSX Stock opened at $41.03 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 0.86 and a debt-to-equity ratio of 0.51. Boston Scientific has a 1 year low of $34.98 and a 1 year high of $47.49. The firm's fifty day moving average price is $38.31 and its two-hundred day moving average price is $41.24. The firm has a market capitalization of $58.66 billion, a P/E ratio of 70.74, a PEG ratio of 2.22 and a beta of 0.85.

Boston Scientific (NYSE:BSX - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.02. The company had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. Boston Scientific had a net margin of 7.16% and a return on equity of 14.58%. Boston Scientific's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.40 EPS. On average, equities analysts predict that Boston Scientific will post 1.76 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BSX. BTIG Research lifted their price target on shares of Boston Scientific from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, July 28th. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Thursday, April 21st. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $51.00 to $43.00 and set a "buy" rating on the stock in a research report on Wednesday, June 29th. Truist Financial cut their price objective on shares of Boston Scientific from $51.00 to $45.00 and set a "buy" rating on the stock in a research report on Wednesday, July 20th. Finally, Wolfe Research started coverage on shares of Boston Scientific in a research report on Tuesday, July 5th. They issued an "outperform" rating and a $43.00 price objective on the stock. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $46.55.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the completion of the sale, the executive vice president now owns 132,413 shares of the company's stock, valued at approximately $5,031,694. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the completion of the sale, the executive vice president now owns 132,413 shares of the company's stock, valued at approximately $5,031,694. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nelda J. Connors sold 16,088 shares of the business's stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $41.58, for a total transaction of $668,939.04. Following the completion of the sale, the director now directly owns 4,877 shares of the company's stock, valued at approximately $202,785.66. The disclosure for this sale can be found here. Insiders have sold 59,264 shares of company stock worth $2,382,173 in the last ninety days. Insiders own 0.66% of the company's stock.

Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Medtronic Stock Keeps Ticking Forward (BSX)
Medical device maker Medtronic (NYSE: MDT) stock is trading down (-14%) for the year.
Boston Scientific Co. (NYSE:BSX) EVP Sells $847,509.24 in Stock
Boston Scientific (NYSE:BSX) PT Raised to $50.00
Boston Scientific (NYSE:BSX) PT Raised to $45.00
Boston Scientific (NYSE:BSX) Sees Strong Trading Volume
See More Headlines
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Company Calendar

Last Earnings
7/27/2022
Today
8/10/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
10113710
Employees
41,000
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$46.55
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+11.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$1.04 billion
Pretax Margin
8.95%

Debt

Sales & Book Value

Annual Sales
$11.89 billion
Cash Flow
$2.76 per share
Book Value
$11.66 per share

Miscellaneous

Outstanding Shares
1,429,571,000
Free Float
1,420,136,000
Market Cap
$59.84 billion
Optionable
Optionable
Beta
0.85

Social Links















BSX Stock - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BSX shares.
View BSX analyst ratings
or view top-rated stocks.

What is Boston Scientific's stock price forecast for 2022?

12 Wall Street analysts have issued 12-month price objectives for Boston Scientific's shares. Their BSX share price forecasts range from $43.00 to $51.00. On average, they anticipate the company's share price to reach $46.55 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for BSX
or view top-rated stocks among Wall Street analysts.

How have BSX shares performed in 2022?

Boston Scientific's stock was trading at $42.48 at the beginning of the year. Since then, BSX shares have decreased by 1.5% and is now trading at $41.86.
View the best growth stocks for 2022 here
.

Are investors shorting Boston Scientific?

Boston Scientific saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 13,750,000 shares, a drop of 14.3% from the July 15th total of 16,040,000 shares. Based on an average daily volume of 8,290,000 shares, the short-interest ratio is presently 1.7 days.
View Boston Scientific's Short Interest
.

When is Boston Scientific's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BSX earnings forecast
.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) released its earnings results on Wednesday, July, 27th. The medical equipment provider reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.02. The medical equipment provider earned $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. Boston Scientific had a trailing twelve-month return on equity of 14.58% and a net margin of 7.16%. The business's revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $0.40 earnings per share.
Read the conference call transcript
.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $0.43-$0.45 for the period, compared to the consensus estimate of $0.45. The company issued revenue guidance of $3.11 billion-$3.17 billion, compared to the consensus revenue estimate of $3.20 billion.

What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?

947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by many different retail and institutional investors. Top institutional investors include Parnassus Investments LLC (1.10%), Lazard Asset Management LLC (0.89%), abrdn plc (0.59%), Swiss National Bank (0.43%), Pictet Asset Management SA (0.32%) and Jarislowsky Fraser Ltd (0.29%). Insiders that own company stock include Arthur C Butcher, Arthur C Butcher, Daniel J Brennan, David A Pierce, David A Pierce, David S Wichmann, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Ian T Meredith, Jeffrey B Mirviss, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Maulik Nanavaty, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Wendy Carruthers, William F Bruss and Williamson Scott.
View institutional ownership trends
.

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $41.86.

How much money does Boston Scientific make?

Boston Scientific (NYSE:BSX) has a market capitalization of $59.84 billion and generates $11.89 billion in revenue each year. The medical equipment provider earns $1.04 billion in net income (profit) each year or $0.58 on an earnings per share basis.

How many employees does Boston Scientific have?

The company employs 41,000 workers across the globe.

Does Boston Scientific have any subsidiaries?

The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More

When was Boston Scientific founded?

Boston Scientific was founded in 1979.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The official website for the company is www.bostonscientific.com. The medical equipment provider can be reached via phone at (508) 683-4000, via email at bsxinvestorrelations@bsci.com, or via fax at 508-683-5675.

This page (NYSE:BSX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.